Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 100

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Study on the Safety and Effectiveness of Taladegib for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Taladegib
  • Sponsor:Endeavor Biomedicines Inc.

Palliative care

Not recruiting

Study on Midazolam and Morphine for Symptom Relief in Elderly Patients at End of Life

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Morphine
  • Sponsor:UZ Leuven

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Study of alectinib, pemetrexed, carboplatin and cisplatin in patients with resectable stage I-III non-small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Obesity

Not recruiting

Study on the Long-term Weight Loss Effects of Cagrilintide and Semaglutide in Adults with Obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Colorectal cancer+2

Not recruiting

Study on the Safety and Effectiveness of AZD0022 Alone and with Other Cancer Drugs for Adults with KRAS-G12D Mutated Tumors in Lung, Colorectal, and Pancreatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AZD0022
  • Sponsor:AstraZeneca AB

Study on Sotagliflozin for Improving Symptoms in Patients with Hypertrophic Cardiomyopathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sotagliflozin
  • Sponsor:Lexicon Pharmaceuticals Inc.

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Inhibrx Biosciences Inc.

Study on the Long-Term Safety of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Intercept Pharmaceuticals Inc.

Urinary tract infection+1

Not recruiting

Study of meropenem-vaborbactam safety and effectiveness in children aged 3 months to 12 years with complicated urinary tract infection or acute pyelonephritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Meropenem
  • Sponsor:Rempex Pharmaceuticals Inc.

Drug dependence

Not recruiting

Study on How N-acetylcysteine Helps Treat Cannabis Addiction in Adults

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Acetylcysteine
  • Sponsor:UZ Brussel

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.